Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Dermatology Orthopedics Immune Disorders

Novartis's secukinumab extends lead in IL-17 psoriatic arthritis race

This article was originally published in Scrip

Executive Summary

Novartis is planning global regulatory filings for its interleukin-17A inhibitor secukinumab (AIN457) in 2015 after reporting that it met its endpoints in two pivotal Phase III trials in psoriatic arthritis. The latest developments position it to become the first IL-17 inhibitor to reach the market for the indication. However, the lack of data comparing it with current biological therapies may limit its commercial potential.

Table

View full table

Topics

Related Companies

Tags:
Dermatology Orthopedics Immune Disorders
Latest Headlines

Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge

Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

See All
UsernamePublicRestriction

Register

SC026457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By